GlassScriptPhysician profile
Kunali Doshi
NPI 1679133813
$1,521.06
in general payments reported to CMS, 2019-2025
23 companies · $135 in 2025
The $135 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $100 · 2022: $46.83 · 2023: $784 · 2024: $455 · 2025: $135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,374.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,374.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $247.25 | 2021-2025 | Arexvy, Shingrix, Flulaval Quadrivalent |
| Pfizer INC. | $208.96 | 2023-2024 | |
| Lilly USA, LLC | $195.81 | 2023-2024 | Mounjaro, Jardiance |
| Novo Nordisk INC | $155.61 | 2022-2025 | Ozempic, Rybelsus |
| Inspire Medical Systems, INC. | $107.42 | 2023-2025 | Inspire |
| Sumitomo Pharma America, INC. | $94.10 | 2023-2024 | Gemtesa |
| Abbvie INC. | $64.12 | 2023-2024 | Ubrelvy |
| Exact Sciences Corporation | $48.73 | 2023-2024 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $41.93 | 2022-2023 | Farxiga |
| Otsuka America Pharmaceutical, INC. | $38.82 | 2023-2024 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.64 | 2023 | Jardiance |
| Xeris Pharmaceuticals, INC. | $32.97 | 2023 | Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $29.71 | 2023 | |
| Astellas Pharma US INC | $29.45 | 2025 | Veozah |
| Idorsia Pharmaceuticals US INC | $28.48 | 2022-2023 | Quviviq |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $24.62 | 2024 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.92 | 2023 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $23.40 | 2023 | |
| Merck Sharp & Dohme LLC | $21.80 | 2023 | Lagevrio, Belsomra, Steglatro |
| Sanofi-Aventis U.S. LLC | $18.49 | 2023 | |
| Abbott Laboratories | $17.43 | 2024 | Freestyle Libre 3 |
| Amgen INC. | $15.79 | 2023 | Repatha, Otezla |
| Nevro Corp. | $14.61 | 2024 | Senza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kunali Doshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.